The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

TAKE PARTIAL PROFITS ON MYLAN $MYL

February 28, 2017

This post was just published on ZYX Buy Change Alert. MYL is long from an average price of $37.78.  As of this writing it is trading at $41.97.  Consider taking profits on a 15% tranche in the zone of $41.23 to $44.73.  Consider a stop on the remaining in the zone of $39.23 to $39.43.   You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear

Read More »

BIOTECH BEAR ETF LABD: FUND MOVES INTO BIOTECHS AFTER LIQUIDATING PRECIOUS METAL STOCKS $LABD $XBI $IBB $GDX $GDXJ $DUST $NUGT

February 28, 2017

This post was just published on ZYX Buy Change Alert. Please see the Morning Capsule for apparently a fund moving money from liquidating precious metal stocks into biotechs.  This explains the move lower in LABD. The real reason for holding is a potential Trump tweet or mention in his speech tonight of drug prices.  In our analysis, the probability of Trump mentioning drug prices in tonight’s speech is low.  However as the Congress moves towards repeal of Obamacare, details may have a negative impact on biotechs and pharmaceuticals. LABD buy zone remains $9.50 to $12.52.  First target remains $19.50 to $20.  The second

Read More »

TAKE PROFITS ON SEAGATE AND EXIT THE POSITION $STX

February 27, 2017

This post was just published on ZYX Buy Change Alert. If holding, take profits on STX right here around $47.25 and exit the position.   You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

WEEKLY MARKET DIGEST: TRUMP CAUSES NERVOUSNESS IN STOCKS BUT GOLD BENEFITS, BIG BET ON OIL $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

February 24, 2017

  Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. GOLD RISES AND STOCKS FALL ON NERVOUSNESS AHEAD OF A MAJOR SPEECH BY TRUMP February 24, 2017 This is what you need to know today.

Read More »

MNUCHIN MOVES GOLD AND WHY PRECIOUS METAL INVESTORS SHOULD GET TO KNOW MNUCHIN $GLD $SLV $GDX $GDXJ $DUST $NUGT

February 24, 2017

Please click here for long-term annotated chart of GLD. Let us first discuss why gold is moving today and the importance of Mnuchin before discussing The Arora Report updated ratings on gold and silver, long-term allocation to precious metals and short-term trades. Who Is Mnuchin? Steven Mnuchin is the Treasury secretary of Trump’s administration.  The Treasury secretary has always been a powerful position. Mnuchin is especially powerful because of his hedge fund background and the changes Trump is making.  Mnuchin understands the markets. Typically the Treasury secretary does not directly comment on gold but comments on dollar, budgets, taxes, deficits,

Read More »

A NEW IDEA ON MOMENTA, AFTER RECENT GAIN OF 74% THE DIP IS AN OPPORTUNITY TO ENTER AGAIN $MNTA $TEVA $PFE

February 22, 2017

This post was just published on ZYX Buy Change Alert. On February 1st we issued a call to take profits on MNTA.  Depending upon how you traded, your profits would have been 74%. We got out at the top.  Now the stock has fallen providing an opportunity to enter again.  The buy zone is $12 to $15.35, preferably below $14.31.  The stock is trading at $15.30 as of this writing. The target zone is $18 to $20, and $24 to $28 in the event of a buyout.  Stop zone on one-half of the position is $11 to $11.38. Those who are not aggressive may consider

Read More »

11 STOCKS FOR INVESTORS TO LOOK AFTER BUFFETT BACKS DOWN $KHC $UN $UL $GIS $DIA $CPB $K $MDLZ $SJM $CL $KMB $EPC $CLX

February 21, 2017

124 companies in The Arora Report portfolio have been bought out producing handsome gains for our paying subscribers. No other service comes even close to matching this record. If you are interested in making money from buyouts, consider taking a free trial to ZYX Buy Change Alert. President Trump is imploring American companies to invest in America. Warren Buffett, a big supporter of Hillary Clinton and perhaps the best-known American investor, last week made a surprise announcement to move billions of dollars abroad: Kraft Heinz KHC which is controlled by Buffett and Brazilian firm 3G Capital Partners, made a $143 billion

Read More »

INITIATE OR ADD TO BIOTECH BEAR ETF LABD $LABD

February 20, 2017

This post was just published on ZYX Buy Change Alert. (Certain portions of this post are copied from an earlier post but zones are changing.) LABD is a triple leveraged inverse ETF which moves up when biotech and drug stocks go down.  The present prices of drugs in the U. S. are simply unsustainable.  Trump has said that drug companies are getting away with murder.  All it will take is another tweet from Trump or a bill introduced in the Congress by Republicans to make drug and biotech stocks go down. Lately there has been a lot of buying in these stocks

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content